Inetetamab

DB17457InvestigationalProtein Based Therapies

Inetetamab is a trastuzumab analog. It differs from trastuzumab by a two amino acid variation in its Fc domain (allotype variation), and possesses an exact F(ab’)2 of trastuzumab.

Mechanism: Pharmacologically active on Receptor tyrosine-protein kinase erbB-2
Curator reviewed

Resolves to

Targets

P04626ERBB2

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

28Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Inetetamab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account